参考文献

    [1]Kreisl TN，Kim L，Moore K，et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma [J].J Clin Oncol，2009，27(5)：740-745.

    [2]Yang JC，Haworth L，Sherry RM，et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody，for metastatic renal cancer[J].N Engl J Med ......